Biotech M&A in 2015

by | Aug 21, 2015 7:30 pm | Behavioral Health Care | 0 comments

Last Friday, the Biotech sector, represented by the Nasdaq Biotechnology index (NASDAQ: IBB), officially entered a correction phase, based on a 14% drop in valuations since July 20. That could put a damper on a sector that’s seen tremendous M&A activity in 2015, with 117 deals announced so far (vs. 136 total in 2014), and nearly $40 billion in spending (well up from the $21 billion spent in 2014). While the AbbVie’s (NYSE: ABBV) $21 billion takeover of Pharmacyclics (NASDAQ: PCYC) has a lot to do with the large total, billion-dollar deals haven’t been uncommon. Take a look. TargetAcquirerPrice PharmacyclicsAbbVie$21.0 billion NPS PharmaceuticalsShire plc$5.2 billion... Read More »